API Product   :    Ticagrelor*
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Blood coagulation system, other products; Antithrombotic agents
Blood coagulation system, other products; Antithrombotic agents
Originator   :    ASTRAZENECA
CAS No.    :    274693-27-5
Trade Name.   :    BRILINTA
Molecular Weight   :    522.567 g/mol
Molecular Formula   :    C23H28F2N6O4S
It may also be used to prevent heart attack or stroke after certain heart surgeries (such as stent placement, coronary artery bypass graft-CABG, or angioplasty). Ticagrelor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug.
Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y12 receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.